Roman Butler Fullerton & Co’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.08M | Buy |
8,695
+244
| +3% | +$28.6K | 0.26% | 98 |
|
|
2026
Q1 | $1.04M | Buy |
8,451
+54
| +0.6% | +$6.23K | 0.29% | 92 |
|
|
2025
Q4 | $917K | Sell |
8,397
-83
| -1% | -$7.79K | 0.24% | 108 |
|
|
2025
Q3 | $734K | Sell |
8,480
-112
| -1% | -$9.22K | 0.2% | 121 |
|
|
2025
Q2 | $728K | Sell |
8,592
-1,103
| -11% | -$87.7K | 0.21% | 118 |
|
|
2025
Q1 | $760K | Sell |
9,695
-494
| -5% | -$46.1K | 0.3% | 83 |
|
|
2024
Q4 | $998K | Sell |
10,189
-759
| -7% | -$78.2K | 0.32% | 80 |
|
|
2024
Q3 | $1.22M | Buy |
10,948
+295
| +3% | +$35K | 0.37% | 70 |
|
|
2024
Q2 | $1.36M | Sell |
10,653
-570
| -5% | -$73.4K | 0.44% | 56 |
|
|
2024
Q1 | $1.42M | Sell |
11,223
-188
| -2% | -$23.2K | 0.53% | 49 |
|
|
2023
Q4 | $1.38M | Sell |
11,411
-67
| -0.6% | -$6.96K | 0.54% | 48 |
|
|
2023
Q3 | $1.19M | Sell |
11,478
-621
| -5% | -$66.9K | 0.56% | 49 |
|
|
2023
Q2 | $1.28M | Sell |
12,099
-2,517
| -17% | -$286K | 0.59% | 50 |
|
|
2023
Q1 | $1.7M | Buy |
14,616
+2,016
| +16% | +$218K | 0.85% | 25 |
|
|
2022
Q4 | $1.39M | Buy |
12,600
+1,074
| +9% | +$110K | 0.72% | 37 |
|
|
2022
Q3 | $1.05M | Buy |
11,526
+46
| +0.4% | +$4.11K | 0.67% | 44 |
|
|
2022
Q2 | $1.09M | Buy |
11,480
+89
| +0.8% | +$7.89K | 0.61% | 46 |
|
|
2022
Q1 | $935K | Buy |
11,391
+49
| +0.4% | +$3.86K | 0.43% | 72 |
|
|
2021
Q4 | $869K | Buy |
11,342
+300
| +3% | +$23.9K | 0.38% | 77 |
|
|
2021
Q3 | $852K | Buy |
11,042
+15
| +0.1% | +$1.14K | 0.4% | 75 |
|
|
2021
Q2 | $858K | Sell |
11,027
-540
| -5% | -$40.2K | 0.42% | 77 |
|
|
2021
Q1 | $846K | Sell |
11,567
-3,158
| -21% | -$233K | 0.42% | 80 |
|
|
2020
Q4 | $1.15M | Sell |
14,725
-1,149
| -7% | -$87.9K | 0.68% | 47 |
|
|
2020
Q3 | $1.26M | Sell |
15,874
-457
| -3% | -$35.8K | 0.82% | 34 |
|
|
2020
Q2 | $1.21M | Buy |
+16,331
| New | +$1.23M | 0.86% | 32 |
|
|
2020
Q1 | – | Sell |
-18,747
| Closed | -$1.63M | – | 159 |
|
|
2019
Q4 | $1.63M | Sell |
18,747
-437
| -2% | -$35.9K | 1.07% | 22 |
|
|
2019
Q3 | $1.54M | Sell |
19,184
-256
| -1% | -$20.5K | 1.07% | 20 |
|
|
2019
Q2 | $1.55M | Buy |
19,440
+121
| +0.6% | +$9.27K | 1.04% | 21 |
|
|
2019
Q1 | $1.53M | Buy |
19,319
+4,924
| +34% | +$368K | 1.07% | 19 |
|
|
2018
Q4 | $1.02M | Buy |
+14,395
| New | +$1.02M | 0.87% | 26 |
|
Other funds holding MRK
Roman Butler Fullerton & Co's MRK Position: Q2 2026 in Review
Roman Butler Fullerton & Co increased its Merck (MRK) stake by 2.9% in Q2 2026, buying an estimated $28.6K and bringing the position to 8,695 shares worth $1.08M. The position accounts for 0.26% of the portfolio, ranked #98.
Roman Butler Fullerton & Co first reported a position in MRK in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.7M in Q1 2023. 3,844 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Roman Butler Fullerton & Co held 8,695 shares of Merck worth $1.08M as of Q2 2026.
- Roman Butler Fullerton & Co bought 244 Merck shares in Q2 2026, an estimated $28.6K.
- Merck made up 0.26% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #98 holding.
- Roman Butler Fullerton & Co first reported a position in Merck in Q4 2018 and has held it in 30 quarters since.
- Roman Butler Fullerton & Co's Merck position peaked at $1.7M in Q1 2023.
- 3,844 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.